Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 5/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | MMP7 | P09237 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 3/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108738 | 1.00 | MMP13 (0.46) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL14813406 | 0.91 | MMP13 (0.46) | MMP13TGFBR1STSTACR1MAPT | |
| SCHEMBL1689452 | 0.91 | MMP13 (0.46) | MMP13TGFBR1STSTACR1MAPT | |
| SCHEMBL9108211 | 0.87 | MMP13 (0.45) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL9108220 | 0.87 | MMP13 (0.45) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL9110045 | 0.86 | DPP4 (0.45) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL9110055 | 0.86 | DPP4 (0.45) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL1689415 | 0.85 | MMP13 (0.43) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL9107353 | 0.85 | MMP13 (0.45) | MMP13TGFBR1STSTACR1EPHX2 | |
| SCHEMBL14837995 | 0.85 | MMP13 (0.43) | MMP13TGFBR1STSTACR1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637568-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8501964-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | MMP13 4193/4885TGFBR1 871/4885STS 419/4885 |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | MMP13 4193/4885TGFBR1 871/4885STS 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.